Symbols / TOVX $0.38 +0.00% Theriva Biologics, Inc.

Healthcare • Biotechnology • United States • ASE
TOVX Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Steven A. Shallcross CPA
Exch · Country ASE · United States
Market Cap 17.49M
Enterprise Value 7.06M
Income -25.25M
Sales —
FCF (ttm) -5.98M
Book/sh 0.43
Cash/sh 0.28
Employees 15
Insider 10d —
IPO Dec 18, 2006
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 0.09
Forward P/E -1.91
PEG —
P/S —
P/B 0.88
P/C —
EV/EBITDA -0.47
EV/Sales —
Quick Ratio 1.69
Current Ratio 1.74
Debt/Eq 17.09
LT Debt/Eq —
EPS (ttm) -2.08
EPS next Y -0.20
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-12
Earnings (prior) 2025-11-12
ROA -25.51%
ROE -137.82%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 45.89M
Shs Float 45.14M
Insider Own 1.63%
Instit Own 2.86%
Short Float 5.55%
Short Ratio 0.14
Short Interest 2.54M
52W High 1.47
vs 52W High -74.08%
52W Low 0.16
vs 52W Low 138.12%
Beta 0.47
Impl. Vol. —
Rel Volume 0.26
Avg Volume 25.99M
Volume 6.79M
Target (mean) $2.50
Tgt Median $2.50
Tgt Low $1.00
Tgt High $4.00
# Analysts 2
Recom None
Prev Close $0.38
Price $0.38
Change 0.00%
About

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$2.50
Mean price target
2. Current target
$0.38
Latest analyst target
3. DCF / Fair value
$-2.34
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.38
Low
$1.00
High
$4.00
Mean
$2.50

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-31 up Maxim Group Hold → Buy $1
2025-05-08 down Maxim Group Buy → Hold —
2024-11-13 main Maxim Group Buy → Buy $6
News
RSS: Latest TOVX news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
24.05
+23.80%
19.43
-9.35%
21.43
-0.70%
21.58
Research And Development
8.60
-28.48%
12.03
-15.93%
14.31
+22.08%
11.72
Selling General And Administration
15.45
+108.86%
7.40
+3.88%
7.12
-27.77%
9.86
General And Administrative Expense
15.45
+108.86%
7.40
+3.88%
7.12
-27.77%
9.86
Other Gand A
15.45
+108.86%
7.40
+3.88%
7.12
-27.77%
9.86
Total Expenses
24.05
+23.80%
19.43
-9.35%
21.43
-0.70%
21.58
Operating Income
-24.05
-23.80%
-19.43
+9.35%
-21.43
+0.70%
-21.58
Total Operating Income As Reported
-24.05
+8.71%
-26.35
-22.93%
-21.43
+0.70%
-21.58
EBITDA
-23.94
-24.12%
-19.29
+9.42%
-21.30
+0.93%
-21.50
Normalized EBITDA
-23.97
-93.81%
-12.37
+41.94%
-21.30
+0.73%
-21.45
Reconciled Depreciation
0.11
-21.17%
0.14
+1.48%
0.14
+58.82%
0.09
EBIT
-24.05
-23.80%
-19.43
+9.35%
-21.43
+0.70%
-21.58
Total Unusual Items
0.03
+100.36%
-6.92
-230866.67%
0.00
+107.32%
-0.04
Total Unusual Items Excluding Goodwill
0.03
+100.36%
-6.92
-230866.67%
0.00
+107.32%
-0.04
Special Income Charges
0.00
+100.00%
-6.92
0.00
—
Impairment Of Capital Assets
0.00
-100.00%
5.59
0.00
—
Write Off
0.00
-100.00%
1.32
0.00
—
Net Income
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Pretax Income
-23.74
+7.46%
-25.65
-28.34%
-19.99
+5.31%
-21.11
Net Non Operating Interest Income Expense
0.29
-58.82%
0.70
-51.56%
1.44
+181.05%
0.51
Net Interest Income
0.29
-58.82%
0.70
-51.56%
1.44
+181.05%
0.51
Interest Income Non Operating
0.29
-58.82%
0.70
-51.56%
1.44
+181.05%
0.51
Interest Income
0.29
-58.82%
0.70
-51.56%
1.44
+181.05%
0.51
Other Income Expense
0.03
+100.36%
-6.92
-230866.67%
0.00
+107.32%
-0.04
Gain On Sale Of Security
0.03
+725.00%
-0.00
-233.33%
0.00
+107.32%
-0.04
Tax Provision
0.00
0.00
+100.00%
-1.64
-15.09%
-1.43
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+21.48%
0.00
Tax Effect Of Unusual Items
0.00
0.00
-100.00%
0.00
+108.89%
-0.00
Net Income Including Noncontrolling Interests
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Net Income From Continuing Operation Net Minority Interest
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Net Income From Continuing And Discontinued Operation
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Net Income Continuous Operations
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Minority Interests
—
—
—
0.00
Normalized Income
-23.76
-26.88%
-18.73
-2.06%
-18.35
+6.59%
-19.65
Net Income Common Stockholders
-25.25
+1.57%
-25.65
-39.81%
-18.35
+8.37%
-20.02
Otherunder Preferred Stock Dividend
1.51
0.00
0.00
-100.00%
0.34
Diluted EPS
-2.08
+89.07%
-19.03
+33.18%
-28.48
+13.04%
-32.75
Basic EPS
-2.08
+89.07%
-19.03
+33.18%
-28.48
+13.04%
-32.75
Basic Average Shares
12.14
+800.56%
1.35
+109.24%
0.64
+5.09%
0.61
Diluted Average Shares
12.14
+800.56%
1.35
+109.24%
0.64
+5.09%
0.61
Diluted NI Availto Com Stockholders
-25.25
+1.57%
-25.65
-39.81%
-18.35
+8.37%
-20.02
Preferred Stock Dividends
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
38.24
+8.17%
35.35
-35.98%
55.22
-23.16%
71.86
Current Assets
17.47
+7.28%
16.28
-40.59%
27.40
-39.80%
45.52
Cash Cash Equivalents And Short Term Investments
13.06
+12.46%
11.61
-49.91%
23.18
-44.53%
41.79
Cash And Cash Equivalents
13.06
+12.46%
11.61
-49.91%
23.18
-44.53%
41.79
Receivables
3.83
+15.41%
3.32
+71.29%
1.94
+739.83%
0.23
Other Receivables
0.45
—
—
0.14
Taxes Receivable
3.38
+1.81%
3.32
+71.29%
1.94
+2129.89%
0.09
Prepaid Assets
0.58
-57.30%
1.35
-40.99%
2.29
-34.74%
3.50
Total Non Current Assets
20.77
+8.92%
19.07
-31.44%
27.82
+5.60%
26.34
Net PPE
1.02
-33.53%
1.54
-29.30%
2.18
+41.26%
1.54
Gross PPE
1.99
-19.62%
2.48
-22.18%
3.18
+32.13%
2.41
Accumulated Depreciation
-0.97
-3.32%
-0.94
+6.69%
-1.00
-15.84%
-0.86
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
0.65
-9.60%
0.72
-21.25%
0.91
+0.55%
0.91
Other Properties
1.25
-25.06%
1.66
-23.53%
2.18
+54.66%
1.41
Leases
0.09
+0.00%
0.09
+0.00%
0.09
+0.00%
0.09
Goodwill And Other Intangible Assets
19.62
+13.03%
17.36
-31.81%
25.45
+3.16%
24.68
Goodwill
—
0.00
-100.00%
5.70
+3.17%
5.53
Other Intangible Assets
19.62
+13.03%
17.36
-12.13%
19.75
+3.16%
19.15
Non Current Prepaid Assets
—
—
—
0.02
Other Non Current Assets
0.13
-25.15%
0.17
-5.00%
0.18
+47.54%
0.12
Total Liabilities Net Minority Interest
22.86
+40.35%
16.29
+4.92%
15.52
-10.26%
17.30
Current Liabilities
10.01
+32.02%
7.58
+12.57%
6.74
-4.56%
7.06
Payables And Accrued Expenses
7.58
+46.22%
5.18
+0.56%
5.16
+38.31%
3.73
Payables
1.01
+18.04%
0.86
+11.56%
0.77
-15.85%
0.92
Accounts Payable
1.01
+18.04%
0.86
+11.56%
0.77
-15.85%
0.92
Current Accrued Expenses
6.57
+51.82%
4.33
-1.37%
4.38
+55.94%
2.81
Pensionand Other Post Retirement Benefit Plans Current
0.15
-18.18%
0.19
+47.24%
0.13
+45.98%
0.09
Current Debt And Capital Lease Obligation
0.61
+1.00%
0.60
+9.09%
0.55
+101.47%
0.27
Current Debt
0.06
-6.56%
0.06
-3.17%
0.06
+10.53%
0.06
Other Current Borrowings
0.06
-6.56%
0.06
-3.17%
0.06
+10.53%
0.06
Current Capital Lease Obligation
0.55
+1.86%
0.54
+10.68%
0.49
+125.46%
0.22
Current Deferred Liabilities
1.68
+3.78%
1.61
+78.15%
0.91
0.00
Other Current Liabilities
—
—
—
2.97
Total Non Current Liabilities Net Minority Interest
12.84
+47.61%
8.70
-0.96%
8.78
-14.19%
10.24
Long Term Debt And Capital Lease Obligation
2.02
+109.64%
0.96
-39.84%
1.60
+13.92%
1.41
Long Term Debt
1.67
+1716.30%
0.09
-43.21%
0.16
-26.70%
0.22
Long Term Capital Lease Obligation
0.35
-59.68%
0.87
-39.46%
1.44
+21.48%
1.19
Non Current Deferred Liabilities
0.81
+6.96%
0.76
-15.89%
0.91
-44.00%
1.62
Non Current Deferred Taxes Liabilities
0.81
+6.96%
0.76
-15.89%
0.91
-44.00%
1.62
Other Non Current Liabilities
10.00
+43.47%
6.97
+11.14%
6.27
-12.99%
7.21
Stockholders Equity
15.38
-19.32%
19.07
-51.97%
39.70
-27.25%
54.56
Common Stock Equity
15.38
-19.32%
19.07
-48.42%
36.96
-28.68%
51.83
Capital Stock
0.03
+1033.33%
0.00
-99.89%
2.73
-0.55%
2.75
Common Stock
0.03
+1033.33%
0.00
+200.00%
0.00
-93.75%
0.02
Preferred Stock
—
0.00
-100.00%
2.73
+0.00%
2.73
Share Issued
35.72
+1170.50%
2.81
+293.33%
0.71
+12.78%
0.63
Ordinary Shares Number
35.69
+1182.62%
2.78
+305.65%
0.69
+13.38%
0.60
Treasury Shares Number
0.03
+0.00%
0.03
+0.00%
0.03
+0.03%
0.03
Additional Paid In Capital
373.59
+5.09%
355.50
+2.59%
346.54
+0.81%
343.75
Retained Earnings
-358.71
-7.09%
-334.97
-8.29%
-309.32
-6.31%
-290.97
Gains Losses Not Affecting Retained Earnings
0.76
+164.09%
-1.18
-3781.25%
0.03
+104.71%
-0.68
Treasury Stock
0.29
+0.00%
0.29
+0.00%
0.29
+0.00%
0.29
Minority Interest
—
—
—
—
Other Equity Adjustments
0.76
+164.09%
-1.18
-3781.25%
0.03
+104.71%
-0.68
Total Equity Gross Minority Interest
15.38
-19.32%
19.07
-51.97%
39.70
-27.25%
54.56
Total Capitalization
17.05
-10.99%
19.16
-51.93%
39.86
-27.24%
54.78
Working Capital
7.45
-14.29%
8.70
-57.92%
20.66
-46.27%
38.46
Invested Capital
17.11
-10.97%
19.22
-48.32%
37.19
-28.63%
52.11
Total Debt
2.63
+67.99%
1.56
-27.34%
2.15
+28.14%
1.68
Capital Lease Obligations
0.90
-36.19%
1.41
-26.80%
1.93
+37.49%
1.40
Net Tangible Assets
-4.24
-347.86%
1.71
-88.00%
14.24
-52.35%
29.89
Tangible Book Value
-4.24
-347.86%
1.71
-85.15%
11.51
-57.62%
27.16
Current Deferred Taxes Liabilities
1.68
+3.78%
1.61
+78.15%
0.91
0.00
Preferred Stock Equity
—
—
2.73
+0.00%
2.73
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-16.67
+1.58%
-16.94
+10.84%
-19.00
+0.45%
-19.08
Cash Flow From Continuing Operating Activities
-16.67
+1.58%
-16.94
+10.84%
-19.00
+0.45%
-19.08
Net Income From Continuing Operations
-23.74
+7.46%
-25.65
-39.81%
-18.35
+6.79%
-19.68
Depreciation Amortization Depletion
0.11
-21.17%
0.14
+1.48%
0.14
+58.82%
0.09
Depreciation
0.11
-21.17%
0.14
+1.48%
0.14
+58.82%
0.09
Depreciation And Amortization
0.11
-21.17%
0.14
+1.48%
0.14
+58.82%
0.09
Other Non Cash Items
9.55
+729.97%
1.15
+157.46%
-2.00
-188.08%
2.27
Stock Based Compensation
0.65
-2.53%
0.67
+21.56%
0.55
+16.21%
0.47
Asset Impairment Charge
0.00
-100.00%
6.92
0.00
—
Deferred Tax
-0.19
+78.83%
-0.89
+45.85%
-1.64
-15.09%
-1.43
Deferred Income Tax
-0.19
+78.83%
-0.89
+45.85%
-1.64
-15.09%
-1.43
Operating Gains Losses
0.00
—
—
—
Change In Working Capital
-3.06
-521.21%
0.73
-68.56%
2.31
+386.48%
-0.81
Change In Prepaid Assets
0.46
-50.05%
0.91
-30.52%
1.31
+461.98%
-0.36
Change In Payables And Accrued Expense
-2.95
-1100.68%
0.29
-79.18%
1.42
+544.20%
-0.32
Change In Accrued Expense
-3.02
-1856.40%
0.17
-89.07%
1.57
+2284.85%
0.07
Change In Payable
0.07
-43.90%
0.12
+178.34%
-0.16
+59.22%
-0.39
Change In Account Payable
0.07
-43.90%
0.12
+178.34%
-0.16
+59.22%
-0.39
Change In Other Working Capital
—
—
—
0.33
Change In Other Current Assets
—
—
—
—
Change In Other Current Liabilities
-0.56
-16.60%
-0.48
-14.22%
-0.42
-240.32%
-0.12
Investing Cash Flow
-0.04
-3400.00%
-0.00
+99.50%
-0.20
+95.40%
-4.40
Cash Flow From Continuing Investing Activities
-0.04
-3400.00%
-0.00
+99.50%
-0.20
+95.40%
-4.40
Net PPE Purchase And Sale
-0.04
-3400.00%
-0.00
+99.50%
-0.20
-74.14%
-0.12
Purchase Of PPE
-0.04
-3400.00%
-0.00
+99.50%
-0.20
-74.14%
-0.12
Capital Expenditure
-0.04
-3400.00%
-0.00
+99.50%
-0.20
-74.14%
-0.12
Net Business Purchase And Sale
—
—
0.00
+100.00%
-4.28
Purchase Of Business
—
—
0.00
+100.00%
-4.28
Financing Cash Flow
18.19
+231.02%
5.50
+779.36%
0.62
+132.38%
-1.93
Cash Flow From Continuing Financing Activities
18.19
+231.02%
5.50
+779.36%
0.62
+132.38%
-1.93
Net Issuance Payments Of Debt
1.44
+2244.78%
-0.07
+10.67%
-0.07
+94.55%
-1.38
Issuance Of Debt
1.51
0.00
—
—
Repayment Of Debt
-0.07
-4.48%
-0.07
+10.67%
-0.07
+94.55%
-1.38
Long Term Debt Issuance
1.51
0.00
—
—
Long Term Debt Payments
-0.07
-4.48%
-0.07
+10.67%
-0.07
+94.55%
-1.38
Net Long Term Debt Issuance
1.44
+2244.78%
-0.07
+10.67%
-0.07
+94.55%
-1.38
Net Common Stock Issuance
13.52
+143.09%
5.56
+150.70%
2.22
+870.49%
-0.29
Common Stock Payments
—
—
0.00
+100.00%
-0.29
Repurchase Of Capital Stock
—
—
0.00
+100.00%
-0.29
Proceeds From Stock Option Exercised
3.95
0.00
—
0.00
Net Other Financing Charges
-0.71
—
-1.52
+49.37%
-3.00
Changes In Cash
1.49
+113.01%
-11.44
+38.39%
-18.57
+26.90%
-25.41
Effect Of Exchange Rate Changes
-0.09
+30.30%
-0.13
-300.00%
-0.03
-3.13%
-0.03
Beginning Cash Position
11.71
-49.72%
23.28
-44.42%
41.88
-37.79%
67.33
End Cash Position
13.10
+11.94%
11.71
-49.72%
23.28
-44.42%
41.88
Free Cash Flow
-16.70
+1.38%
-16.94
+11.77%
-19.20
+0.00%
-19.20
Common Stock Issuance
13.52
+143.09%
5.56
+150.70%
2.22
0.00
Issuance Of Capital Stock
13.52
+143.09%
5.56
+150.70%
2.22
-18.84%
2.73
Net Preferred Stock Issuance
—
—
0.00
-100.00%
2.73
Preferred Stock Issuance
—
—
0.00
-100.00%
2.73
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category